Wells Fargo raised the firm’s price target on Kymera Therapeutics to $38 from $30 and keeps an Equal Weight rating on the shares. The firm cites management’s commentary on KT-261’s preclinical tox profile though it sees only incremental catalysts through the rest of 2024 ahead of KT-261’s Phase 1 data next year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $60 from $46 at H.C. Wainwright
- Kymera Therapeutics reports Q2 EPS (58c), consensus (68c)
- Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
- KYMR Upcoming Earnings Report: What to Expect?
Questions or Comments about the article? Write to editor@tipranks.com